Price
No data yet.
Social Signal Score
Revenue
$0.00Company Profile
- CEO
- Ethan Shen
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 14
- Beta
- -0.12
- Country
- TW
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 47.15
Financials
YDES has only 7 quarterly periods on file — the charts below show the full history available.
Net Income
$-2.21M-420.0%EBITDA
$-2.22M-427.7%Free Cash Flow
$-298.2KEPS (diluted)
$-0.65-506.3%Shares Outstanding (diluted)
3.41M-20.7%Operating Expenses
$389.2KCash & Debt
$6.3KReturn of Capital
$584.4KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $596.8K | $-8.31M | $-0.12 |
| 2024 | $510.4K | $-1.41M | $-0.56 |
| 2023 | $350.1K | $13.6K | $0.00 |
| 2022 | $0.00 | $3.79M | $0.41 |
| 2021 | $0.00 | $8.70M | $0.59 |
| 2020 | $0.00 | $-2.54M | $-0.17 |
Valuation
YDEShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80+0.00%Social Signal Score
Mentions (4)
- Newsglobenewswire.com·8h ago·Negative
… Assessment for Corporate Wellness Programs TAIPEI, Taiwan, and BOTHELL, Wash., Oct. 20, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection and ophthalmologic innovations, today announced a strategic collaboration with EG BioMed Co., Ltd., a Taiwan registered company and an affiliate of YD Bio (“EG BioMed”), and digital health provider JoiiUp. The partnership integrates an AI Cancer Risk Ass…
View source ↗ - Newsglobenewswire.com·14d ago·Neutral
YD Bio and EG BioMed Launch AI-Based 10-Cancer Risk Factor Assessment TAIPEI, Taiwan, and BOTHELL, Wash., Oct. 06, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that the Company and EG BioMed Co., Ltd.
View source ↗ - Newsglobenewswire.com·49d ago·Neutral
YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026 TAIPEI, Taiwan, Aug. 31, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation–based cancer detection technology and ophthalmologic innovations, today announced its financial results for the six months ended June 30, 2026.
View source ↗ - Newsglobenewswire.com·56d ago·Negative
… Disease Healthcare Association and the Future Health Institute TAIPEI, Taiwan, Aug. 25, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation–based cancer detection technology and ophthalmologic innovations, today announced the publication of a peer-reviewed review article in Nutrients, an international open-access journal published by MDPI (Multidisciplinary Digital Publishing Institute). The article, titled “Beyon…
View source ↗
Insider trading
Open-market buys and sells by YDES officers and directors.
- Bought
- $129k
- Sold
- —
3 trades
0 trades
- Shen Ethan Phdbought
- Shen Ethan Phdbought
- Shen Ethan Phdbought
26 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in YDES.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.